{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:58:13Z","timestamp":1783486693675,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T00:00:00Z","timestamp":1627430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T00:00:00Z","timestamp":1627430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s12020-021-02833-8","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T17:02:46Z","timestamp":1627491766000},"page":"228-234","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real world evidence in effectiveness, safety, and cost savings of generic levothyroxine: a systematic review"],"prefix":"10.1007","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4624-9963","authenticated-orcid":false,"given":"Jingjing","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaniz Afroz","family":"Tanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,28]]},"reference":[{"issue":"12","key":"2833_CR1","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1089\/thy.2012.0205","volume":"22","author":"JR Garber","year":"2012","unstructured":"J.R. Garber, R.H. Cobin, H. Gharib, J.V. Hennessey, I. Klein, J.I. Mechanick, R. Pessah-Pollack, P.A. Singer, K.A. Woeber, American Association of Clinical Endocrinologists, and American Thyroid Association Taskforce On Hypothyroidism in Adults, Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid 22(12), 1200\u20131235 (2012)","journal-title":"Thyroid"},{"issue":"6","key":"2833_CR2","doi-asserted-by":"publisher","first-page":"457","DOI":"10.4158\/1934-2403-8.6.457","volume":"8","author":"HJ Baskin","year":"2002","unstructured":"H.J. Baskin, R.H. Cobin, D.S. Duick, H. Gharib, R.B. Guttler, M.M. Kaplan, R.L. Segal, American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr. Pract.: Off. J. Am. College Endocrinol. Am. Assoc. Clin. Endocrinol. 8(6), 457\u2013469 (2002)","journal-title":"Endocr. Pract.: Off. J. Am. College Endocrinol. Am. Assoc. Clin. Endocrinol."},{"key":"2833_CR3","unstructured":"U.S. Food and Drug Administration. Abbreviated New Drug Application (ANDA). https:\/\/www.fda.gov\/drugs\/types-applications\/abbreviated-new-drug-application-anda. Accessed 20 Jun 2021"},{"key":"2833_CR4","unstructured":"U.S. Food and Drug Administration. Generic drug facts. https:\/\/www.fda.gov\/drugs\/generic-drugs\/generic-drug-facts. Accessed 20 Jun 2021"},{"issue":"4","key":"2833_CR5","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.yebeh.2008.06.001","volume":"13","author":"MJ Berg","year":"2008","unstructured":"M.J. Berg, R.A. Gross, L.S. Haskins, W.M. Zingaro, K.J. Tomaszewski, Generic substitution in the treatment of epilepsy: patient and physician perceptions. Epilepsy Behav. 13(4), 693\u2013699 (2008)","journal-title":"Epilepsy Behav."},{"key":"2833_CR6","doi-asserted-by":"publisher","first-page":"E142","DOI":"10.5888\/pcd9.120010","volume":"9","author":"K Sewell","year":"2012","unstructured":"K. Sewell, S. Andreae, E. Luke, M.M. Safford, Perceptions of and barriers to use of generic medications in a rural African American population, Alabama, 2011. Prev. Chronic Dis. 9, E142 (2012)","journal-title":"Prev. Chronic Dis."},{"issue":"6","key":"2833_CR7","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.sapharm.2011.12.004","volume":"8","author":"AJ Keenum","year":"2012","unstructured":"A.J. Keenum, J.E. Devoe, D.J. Chisolm, L.S. Wallace, Generic medications for you, but brand-name medications for me. Res. Soc. Adm. Pharm. 8(6), 574\u2013578 (2012)","journal-title":"Res. Soc. Adm. Pharm."},{"issue":"2","key":"2833_CR8","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1377\/hlthaff.28.2.546","volume":"28","author":"WH Shrank","year":"2009","unstructured":"W.H. Shrank, E.R. Cox, M.A. Fischer, J. Mehta, N.K. Choudhry, Patients\u2019 perceptions of generic medications\u2019. Health Aff 28(2), 546\u2013556 (2009)","journal-title":"Health Aff"},{"issue":"2","key":"2833_CR9","doi-asserted-by":"publisher","first-page":"126","DOI":"10.7326\/0003-4819-141-2-200407200-00011","volume":"141","author":"TA Brennan","year":"2004","unstructured":"T.A. Brennan, T.H. Lee, Allergic to generics. Ann. Intern. Med. 141(2), 126\u2013130 (2004)","journal-title":"Ann. Intern. Med."},{"issue":"5","key":"2833_CR10","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1111\/j.1475-6773.2006.00579.x","volume":"41","author":"AJ O\u2019Malley","year":"2006","unstructured":"A.J. O\u2019Malley, R.G. Frank, A. Kaddis, B.M. Rothenberg, B.J. McNeil, Impact of alternative interventions on changes in generic dispensing rates. Health Serv. Res. 41(5), 1876\u20131894 (2006)","journal-title":"Health Serv. Res."},{"issue":"8","key":"2833_CR11","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/14740338.2018.1503648","volume":"17","author":"J Qian","year":"2018","unstructured":"J. Qian, A.U. Mishuk, R.A. Hansen, Does public perception bias lead to more frequent reporting of adverse events: branded vs generic drugs. Expert Opinion Drug Saf. 17(8), 753\u2013756 (2018)","journal-title":"Expert Opinion Drug Saf."},{"key":"2833_CR12","unstructured":"American Thyroid Association. AACE, TES, and ATA joint position statement on the use and interchangeability of thyroxine products. (2004). https:\/\/www.thyroid.org\/thyroxine-products-joint-position-statement\/. Accessed 4 Feb 2020"},{"issue":"10","key":"2833_CR13","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","volume":"62","author":"D Moher","year":"2009","unstructured":"D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, Preferred Reporting Items for Systematic Reviews and Meta-analyses: the PRISMA statement. J. Clin. Epidemiol. 62(10), 1006\u20131012 (2009)","journal-title":"J. Clin. Epidemiol."},{"key":"2833_CR14","unstructured":"U.S. Food and Drug Administration. Real-world data (RWD) and real-world evidence (RWE) are playing an increasing role in health care decisions. https:\/\/www.fda.gov\/science-research\/science-and-research-special-topics\/real-world-evidence. Accessed 20 Mar 2021"},{"key":"2833_CR15","unstructured":"National Heart, Lung, and Blood Institute. Study quality assessment tools. https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools. Accessed 15 Aug 2020"},{"issue":"9","key":"2833_CR16","doi-asserted-by":"publisher","first-page":"e2017645","DOI":"10.1001\/jamanetworkopen.2020.17645","volume":"3","author":"JP Brito","year":"2020","unstructured":"J.P. Brito, J.S. Ross, L. Sangaralingham, S.K. Dutcher, D.J. Graham, Z. Wang, Y. Wu, X. Yao, R.C. Smallridge, V. Bernet, N.D. Shah, K.J. Lipska, Comparative effectiveness of generic vs brand-name levothyroxine in achieving normal thyrotropin levels. JAMA Netw. Open 3(9), e2017645 (2020)","journal-title":"JAMA Netw. Open"},{"issue":"4","key":"2833_CR17","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/1475-6773.00162","volume":"38","author":"MA Fischer","year":"2003","unstructured":"M.A. Fischer, J. Avorn, Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans. Health Serv. Res. 38(4), 1051\u20131063 (2003)","journal-title":"Health Serv. Res."},{"issue":"3","key":"2833_CR18","doi-asserted-by":"publisher","first-page":"357","DOI":"10.4158\/EP0362.OR","volume":"16","author":"JV Hennessey","year":"2010","unstructured":"J.V. Hennessey, A.O. Malabanan, B.R. Haugen, E.G. Levy, Adverse event reporting in patients treated with levothyroxine: results of the pharmacovigilance task force survey of the american thyroid association, american association of clinical endocrinologists, and the endocrine society. Endocr. Pract. 16(3), 357\u2013370 (2010)","journal-title":"Endocr. Pract."},{"issue":"9","key":"2833_CR19","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1080\/03007995.2018.1486293","volume":"34","author":"Z Hepp","year":"2018","unstructured":"Z. Hepp, K. Wyne, S.R. Manthena, S. Wang, V. Gossain, Adherence to thyroid hormone replacement therapy: a retrospective, claims database analysis. Current Med. Res. Opinion 34(9), 1673\u20131678 (2018)","journal-title":"Current Med. Res. Opinion"},{"issue":"2","key":"2833_CR20","first-page":"127","volume":"3","author":"M Katz","year":"2010","unstructured":"M. Katz, J. Scherger, S. Conard, L. Montejano, S. Chang, Healthcare costs associated with switching from brand to generic levothyroxine. Am. Health Drug Benefits 3(2), 127\u2013134 (2010)","journal-title":"Am. Health Drug Benefits"},{"issue":"2","key":"2833_CR21","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1210\/jc.2012-3558","volume":"98","author":"JP Lomenick","year":"2013","unstructured":"J.P. Lomenick, L. Wang, S.B. Ampah, B.R. Saville, F.I. Greenwald, Generic levothyroxine compared with synthroid in young children with congenital hypothyroidism. J. Clin. Endocrinol. Metab. 98(2), 653\u2013658 (2013)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"2833_CR22","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1210\/jc.2012-3125","volume":"98","author":"JM Carswell","year":"2013","unstructured":"J.M. Carswell, J.H. Gordon, E. Popovsky, A. Hale, R.S. Brown, Generic and brand-name L-thyroxine are not bioequivalent for children with severe congenital hypothyroidism. J. Clin. Endocrinol. Metab. 98(2), 610\u2013617 (2013)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"15","key":"2833_CR23","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1001\/jama.1997.03540390035032","volume":"277","author":"BJ Dong","year":"1997","unstructured":"B.J. Dong, W.W. Hauck, J.G. Gambertoglio, L. Gee, J.R. White, J.L. Bubp, F.S. Greenspan, Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism. JAMA 277(15), 1205\u20131213 (1997)","journal-title":"JAMA"},{"issue":"7","key":"2833_CR24","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.mayocp.2018.11.030","volume":"94","author":"RC Smallridge","year":"2019","unstructured":"R.C. Smallridge, L.R. Sangaralingham, R. Mwangi, F. Kusumoto, H. Van Houten, V. Bernet, Comparison of incident cardiovascular event rates between generic and brand l-thyroxine for the treatment of hypothyroidism. Mayo Clin. Proc. 94(7), 1190\u20131198 (2019)","journal-title":"Mayo Clin. Proc."},{"issue":"10","key":"2833_CR25","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1345\/aph.1M141","volume":"43","author":"BM Davit","year":"2009","unstructured":"B.M. Davit, P.E. Nwakama, G.J. Buehler, D.P. Conner, S.H. Haidar, D.T. Patel, Y. Yang, L.X. Yu, J. Woodcock, Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann. Pharmacother. 43(10), 1583\u20131597 (2009)","journal-title":"Ann. Pharmacother."},{"issue":"2","key":"2833_CR26","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1007\/s12020-020-02211-w","volume":"68","author":"N Huo","year":"2020","unstructured":"N. Huo, L. Chen, A. Ullah Mishuk, C. Li, R.A. Hansen, I. Harris, Z. Kiptanui, Z. Wang, S.K. Dutcher, J. Qian, Generic levothyroxine initiation and substitution among Medicare and Medicaid populations: a new user cohort study. Endocrine 68(2), 336\u2013348 (2020)","journal-title":"Endocrine"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02833-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-021-02833-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02833-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T06:57:41Z","timestamp":1633676261000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-021-02833-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,28]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["2833"],"URL":"https:\/\/doi.org\/10.1007\/s12020-021-02833-8","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,28]]},"assertion":[{"value":"22 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}